Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Dow
McKesson
Harvard Business School
Express Scripts

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LYNPARZA

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Lynparza

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01116648 Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Active, not recruiting National Cancer Institute (NCI) Phase 1/Phase 2 2010-03-01 This partially randomized phase I/II trial studies the side effects and the best dose of cediranib maleate and olaparib and to see how well cediranib maleate and olaparib work compared to olaparib alone in treating patients with ovarian, fallopian tube, peritoneal, or triple-negative breast cancer that has returned after a period of improvement. Cediranib maleate may help keep cancer cells from growing by affecting their blood supply. Olaparib may stop cancer cells from growing abnormally. The combination of cediranib maleate and olaparib may help to keep cancer from growing.
NCT02032823 Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer Recruiting Br.E.A.S.T. -Data Center & Operational Office Institut Jules Bordet Phase 3 2014-04-01 Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
NCT02032823 Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer Recruiting Breast International Group Phase 3 2014-04-01 Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
NCT02032823 Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer Recruiting Frontier Science & Technology Research Foundation, Inc. Phase 3 2014-04-01 Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
NCT02032823 Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer Recruiting Myriad Genetic Laboratories, Inc. Phase 3 2014-04-01 Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lynparza

Condition Name

Condition Name for Lynparza
Intervention Trials
Recurrent Primary Peritoneal Carcinoma 8
Recurrent Fallopian Tube Carcinoma 8
Breast Cancer 6
BRCA2 Gene Mutation 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Lynparza
Intervention Trials
Adenocarcinoma 18
Carcinoma 18
Ovarian Neoplasms 16
Breast Neoplasms 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Lynparza

Trials by Country

Trials by Country for Lynparza
Location Trials
United States 274
Canada 26
Spain 9
United Kingdom 8
Italy 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Lynparza
Location Trials
Texas 15
Massachusetts 12
Pennsylvania 10
Illinois 10
California 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Lynparza

Clinical Trial Phase

Clinical Trial Phase for Lynparza
Clinical Trial Phase Trials
Phase 4 1
Phase 3 7
Phase 2/Phase 3 2
[disabled in preview] 49
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Lynparza
Clinical Trial Phase Trials
Not yet recruiting 42
Recruiting 32
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Lynparza

Sponsor Name

Sponsor Name for Lynparza
Sponsor Trials
AstraZeneca 37
National Cancer Institute (NCI) 30
M.D. Anderson Cancer Center 8
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Lynparza
Sponsor Trials
Other 65
Industry 64
NIH 30
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Harvard Business School
McKesson
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.